Compare Eli Lilly And Co (LLY) vs Western Alliance Bancorporation (WAL) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Western Alliance Bancorporation (WAL) trades at $80.97, down 1.62% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with a Q2 2026 EPS estimate of $2.33. Strong profitability is evident with a net income margin of 25.63% and ROE of 13.47%, while valuation ratios like a P/E of 9.58 suggest potential undervaluation. Recent news highlights operational achievements, including being named Arizona's #1 bank by Forbes in June 2026.

The outlook for WAL is positive, supported by analyst consensus with 79% buy ratings and a $90.67 price target, implying ~12% upside. Investment opportunities include earnings growth and sector leadership, but risks involve negative operating cash flow in 2025 and high interest expenses of $1.83B that could pressure margins if rates rise.